Table 2 Demographic data of patients with serum PSA levels < 4 ng/ml, 4–10 ng/ml, and > 10 ng/ml
Variables | Serum PSA levels (ng/ml) | |||
|---|---|---|---|---|
< 4 (n = 3) | 4–10 (n = 68) | > 10 (n = 83) | p-value | |
Age at MRI (years), mean (SD) | 68.67 (4.73) | 65.53 (6.69) | 67.60 (7.51) | 0.189 |
Prostate volume (cm3) | ||||
Median (IQR) | 29.88 (21.79–31.32) | 55.57 (37.77–77.20) | 59.71 (38.97–76.90) | 0.049 |
PSAD Median (IQR) | 0.05 (0.03–0.08) | 0.13 (0.09–0.22) | 0.32 (0.19–0.79) | < 0.001 |
Pathology, n (%) | ||||
Cancer | 0 (0.00) | 18 (30.51) | 41 (69.49) | 0.006 |
No cancer | 3 (3.16) | 50 (52.63) | 42 (44.21) | |
Gleason score, n (%) | ||||
2 + 3 = 5 | 1 (5.88) | 1 (2.63) | ||
3 + 3 = 6 | 6 (35.29) | 10 (26.32) | ||
3 + 4 = 7 | 8 (47.06) | 8 (21.05) | ||
4 + 3 = 7 | – | 0 (0.00) | 8 (21.05) | |
4 + 4 = 8 | 2 (11.76) | 2 (5.26) | ||
4 + 5 = 9 | 0 (0.00) | 4 (10.53) | ||
5 + 4 = 9 | 0 (0.00) | 4 (10.53) | ||
5 + 5 = 10 | 0 (0.00) | 1 (2.63) | ||